Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression

There are few effective therapies for unresectable or metastatic hepatocellular carcinoma. Recent data have demonstrated efficacy of immune checkpoint blockade in this difficult to treat disease; however, clinical experience is limited. We report a case of hepatocellular carcinoma displaying pseudop...

Descripción completa

Detalles Bibliográficos
Autores principales: Grierson, Patrick, Crites, Danielle, Ruzinova, Marianna B., Yano, Motoyo, Lim, Kian‐Huat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796320/
https://www.ncbi.nlm.nih.gov/pubmed/29404522
http://dx.doi.org/10.1002/hep4.1132
_version_ 1783297483495964672
author Grierson, Patrick
Crites, Danielle
Ruzinova, Marianna B.
Yano, Motoyo
Lim, Kian‐Huat
author_facet Grierson, Patrick
Crites, Danielle
Ruzinova, Marianna B.
Yano, Motoyo
Lim, Kian‐Huat
author_sort Grierson, Patrick
collection PubMed
description There are few effective therapies for unresectable or metastatic hepatocellular carcinoma. Recent data have demonstrated efficacy of immune checkpoint blockade in this difficult to treat disease; however, clinical experience is limited. We report a case of hepatocellular carcinoma displaying pseudoprogression followed by a late response with novel magnetic resonance imaging features following treatment with the anti‐programmed cell death protein 1 agent pembrolizumab. (Hepatology Communications 2018;2:148–151)
format Online
Article
Text
id pubmed-5796320
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57963202018-02-05 Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression Grierson, Patrick Crites, Danielle Ruzinova, Marianna B. Yano, Motoyo Lim, Kian‐Huat Hepatol Commun Brief Reports There are few effective therapies for unresectable or metastatic hepatocellular carcinoma. Recent data have demonstrated efficacy of immune checkpoint blockade in this difficult to treat disease; however, clinical experience is limited. We report a case of hepatocellular carcinoma displaying pseudoprogression followed by a late response with novel magnetic resonance imaging features following treatment with the anti‐programmed cell death protein 1 agent pembrolizumab. (Hepatology Communications 2018;2:148–151) John Wiley and Sons Inc. 2017-12-19 /pmc/articles/PMC5796320/ /pubmed/29404522 http://dx.doi.org/10.1002/hep4.1132 Text en © 2017 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Reports
Grierson, Patrick
Crites, Danielle
Ruzinova, Marianna B.
Yano, Motoyo
Lim, Kian‐Huat
Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression
title Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression
title_full Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression
title_fullStr Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression
title_full_unstemmed Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression
title_short Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression
title_sort distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: a case report of late response after pseudoprogression
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796320/
https://www.ncbi.nlm.nih.gov/pubmed/29404522
http://dx.doi.org/10.1002/hep4.1132
work_keys_str_mv AT griersonpatrick distinctclinicalandmagneticresonancefeaturesofmetastatichepatocellularcarcinomatreatedwithpembrolizumabacasereportoflateresponseafterpseudoprogression
AT critesdanielle distinctclinicalandmagneticresonancefeaturesofmetastatichepatocellularcarcinomatreatedwithpembrolizumabacasereportoflateresponseafterpseudoprogression
AT ruzinovamariannab distinctclinicalandmagneticresonancefeaturesofmetastatichepatocellularcarcinomatreatedwithpembrolizumabacasereportoflateresponseafterpseudoprogression
AT yanomotoyo distinctclinicalandmagneticresonancefeaturesofmetastatichepatocellularcarcinomatreatedwithpembrolizumabacasereportoflateresponseafterpseudoprogression
AT limkianhuat distinctclinicalandmagneticresonancefeaturesofmetastatichepatocellularcarcinomatreatedwithpembrolizumabacasereportoflateresponseafterpseudoprogression

Ejemplares similares